Streetbeat News

Regulatory

TEVA

Teva Pharmaceuticals announced positive final results from the Phase 4 START study of AUSTEDO's 4-week Titration Kit for Huntington's disease (HD) chorea at the 2024 AAN Annual Meeting. The study showed that nearly 80% of patients achieved optimal dosing within four weeks, with significant improvements in symptoms and high patient satisfaction. AUSTEDO is highlighted as the only VMAT2 inhibitor with 3-year data for HD chorea, emphasizing its real-world effectiveness, safety, and adherence.

Portfolio Pulse from Benzinga Newsdesk

April 16, 2024 | 12:18 pm

MNPR

Monopar Therapeutics Inc. (NASDAQ:MNPR) announced the filing of a provisional patent for advancements in its MNPR-101 radiopharmaceutical program, aimed at developing treatments for advanced cancers. The patent covers the MNPR-101-Zr construct, including variations that could enhance its clinical profile. This move is expected to strengthen Monopar's intellectual property around the MNPR-101 program, which is currently in a Phase 1 dosimetry clinical trial for patients with advanced cancers.

Portfolio Pulse from Benzinga Newsdesk

April 16, 2024 | 12:05 pm

BRTX

BioRestorative Therapies' stock price increased following the FDA's approval of a protocol amendment for its Phase 2 BRTX-100 clinical study. This regulatory milestone is significant for the company's progress in developing its therapies.

Portfolio Pulse from Benzinga Newsdesk

April 16, 2024 | 11:58 am

ENLV

Enlivex has received authorization from the Danish Medicines Agency for a Phase I/II trial to evaluate Allocetra in treating knee osteoarthritis. This marks a significant step forward in the development of Allocetra, potentially opening new treatment avenues for patients with this condition.

Portfolio Pulse from Benzinga Newsdesk

April 16, 2024 | 11:57 am

AMD

FTXL

INTC

NVDA

SOXQ

Intel and Nvidia are adapting their AI chip strategies for the Chinese market in response to U.S. sanctions by launching China-specific products with reduced capabilities. Intel plans to release two AI chips, HL-328 and HL-388, while Nvidia is developing three China-specific chips. These moves come as both companies face challenges in China due to the country's push to remove foreign technology from its telecom networks by 2027. Intel's stock has seen a 13% increase over the last 12 months, and its performance can also impact related ETFs like FTXL and SOXQ.

Portfolio Pulse from Anusuya Lahiri

April 16, 2024 | 11:47 am

BRTX

BioRestorative Therapies has received FDA clearance for an amendment to the Phase 2 clinical study protocol of BRTX-100, a significant step forward in its development process.

Portfolio Pulse from Benzinga Newsdesk

April 16, 2024 | 11:46 am

LXEO

Lexeo Therapeutics' stock price increased following the announcement that its gene therapy candidate LX2006, aimed at treating Friedreich's ataxia cardiomyopathy, received FDA Fast Track designation.

Portfolio Pulse from Benzinga Newsdesk

April 16, 2024 | 11:37 am

CYBN

Cybin announced the grant of an additional US patent supporting its CYB003 program for Major Depressive Disorder, potentially strengthening its intellectual property and therapeutic offering.

Portfolio Pulse from Benzinga Newsdesk

April 16, 2024 | 11:35 am

LXEO

Lexeo Therapeutics has received FDA Fast Track Designation for LX2006, an AAV-based gene therapy candidate aimed at treating Friedreich's Ataxia Cardiomyopathy. This designation could accelerate the development and review process for LX2006, potentially bringing it to patients sooner.

Portfolio Pulse from Benzinga Newsdesk

April 16, 2024 | 11:31 am

QQQ

SPY

TSLA

UNH

Wall Street anticipates a mixed open due to Middle-East tensions and rising bond yields, despite earnings optimism. UnitedHealth Group's earnings led to a rise in health benefit stocks, while tech stocks showed premarket weakness. The SPDR S&P 500 ETF Trust and Invesco QQQ ETF saw minor adjustments in premarket trading. Analysts suggest a potential reversal in sentiment, citing historical patterns of recovery post-streaks of declines. Upcoming economic data and Federal Reserve officials' speeches are in focus, alongside earnings reports from major companies.

Portfolio Pulse from Shanthi Rexaline

April 16, 2024 | 11:24 am